PMID-33638809 – Setmelanotide First Approval Review
Markham A. Setmelanotide: First Approval. Drugs. 2021;81(3):397-403.
Quick Reference
| Property | Value |
|---|---|
| PMID | 33638809 |
| DOI | 10.1007/s40265-021-01470-9 |
| Year | 2021 |
| Journal | Drugs |
| Study Type | Narrative Review (Drug Approval Review) |
| Evidence Level | V |
| Sample | N/A (regulatory/pharmacological review) |
| Peptide(s) Studied | Setmelanotide |
Key Findings
- Setmelanotide (Imcivree) received FDA approval on November 27, 2020, for chronic weight management in patients >=6 years with obesity due to POMC, PCSK1, or LEPR deficiency confirmed by genetic testing
- Cyclic octapeptide (8 amino acids) with high MC4R selectivity
- Administered as 3 mg once-daily subcutaneous injection (adults); 2 mg for pediatric patients 6-12 years
- Half-life approximately 11 hours; primarily renally eliminated
- Key pharmacology: restores melanocortin signaling downstream of the leptin-POMC pathway by directly activating MC4R, bypassing the defective upstream components
- Unlike non-selective melanocortin agonists, setmelanotide has reduced MC1R and MC3R activity, limiting (but not eliminating) hyperpigmentation
- Contraindicated in patients without confirmed genetic deficiency — no efficacy in common obesity
Study Design
Narrative drug approval review summarizing the pharmacology, clinical development, regulatory pathway, and approval basis for setmelanotide. Covers preclinical data, Phase 2/3 clinical trials, FDA review considerations, and prescribing information.
Limitations
- Narrative review — not a systematic evaluation
- Limited long-term safety data available at time of publication
- Focused on regulatory approval basis rather than comparative effectiveness
- Does not address off-label use or real-world effectiveness
Clinical Relevance
This approval review is important for the Ageless Pep Academy curriculum because it provides a comprehensive, concise overview of setmelanotide's pharmacology and clinical positioning. The MC4R pathway is central to understanding several peptides in the vault: PT-141 (bremelanotide) acts on MC4R for sexual function, Melanotan I/II are non-selective melanocortin agonists, and the native MSH fragments (like KPV from alpha-MSH) also signal through melanocortin receptors. Setmelanotide represents the most refined therapeutic targeting of MC4R to date, and its approval establishes key principles: (1) genetic confirmation of pathway defect is required, (2) MC4R agonism produces predictable but manageable side effects (hyperpigmentation, injection site reactions), and (3) the melanocortin system is a validated drug target for metabolic disease.
Related
#research #narrative-review #setmelanotide #evidence-level-V #metabolic